Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A RANDOMIZED, 2-ARM, PHASE 3 STUDY OF ELRANATAMAB (PF-06863135) VERSUS LENALIDOMIDE IN PATIENTS WITH NEWLY DIAGNOSED MULTIPLE MYELOMA AFTER UNDERGOING AUTOLOGOUS STEM-CELL TRANSPLANTATION

NCT05317416 is registered in ClinicalTrials.gov with Pfizer as lead sponsor.

NCT NCT05317416
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05317416 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A RANDOMIZED, 2-ARM, PHASE 3 STUDY OF ELRANATAMAB (PF-06863135) VERSUS LENALIDOMIDE IN PATIENTS WITH NEWLY DIAGNOSED MULTIPLE MYELOMA AFTER UNDERGOING AUTOLOGOUS STEM-CELL TRANSPLANTATION
Lead sponsor
Pfizer
Phase
Phase 3
Overall status
Active, not recruiting
Start date
March 25, 2022
Completion date
October 31, 2029
Enrollment
854 (actual)
Sites
209

Conditions

As the registry lists them; a condition with its own page is linked.

multiple myeloma